After several guidance downgrades during the year, Hikma’s FY 16 results came in above our and consensus estimates, with the outperformance primarily coming from the Injectables division. Revenue was up 35% yoy to $1.95bn (+39% at cc), mainly driven by the consolidation of ten months contribution from the Roxane Laboratories acquisition (West-Ward Columbus). Adjusted operating income fell 3% to $382m (the margin plummeted 770bp to 19.6%), mainly impacted by high overhead costs of West-W
03 Apr 2017
Advair approval key for achieving FY 17 guidance
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Advair approval key for achieving FY 17 guidance
Hikma Pharmaceuticals Plc (HIK:LON) | 1,858 817.5 2.4% | Mkt Cap: 4,123m
- Published:
03 Apr 2017 -
Author:
Jyoti Prakash -
Pages:
3
After several guidance downgrades during the year, Hikma’s FY 16 results came in above our and consensus estimates, with the outperformance primarily coming from the Injectables division. Revenue was up 35% yoy to $1.95bn (+39% at cc), mainly driven by the consolidation of ten months contribution from the Roxane Laboratories acquisition (West-Ward Columbus). Adjusted operating income fell 3% to $382m (the margin plummeted 770bp to 19.6%), mainly impacted by high overhead costs of West-W